Scale-up complete for Alzheimer's candidate

Manufacturing scale-up is complete for Avanex Life Sciences' alzheimer's treatment. A Phase I clinical trial of AVANEX 2-73 is set to begin in early 2010.

Some two kilograms of the drug candidate were manufactured by Sweden-based Syntagon, a provider of synthetic organic chemistry services. The contract manufacturer developed a five-step synthetic procedure for production of the compound. In addition, it developed and evaluated analytical methods for the production process.

The compound uses sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease, according to a company announcement.

- here's the announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.